Results -- View - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs With the two market leading drugs both suffering from poor side-effect profiles, and considerable scope for improved efficacy, there is still considerable unmet need in the market.- Scope Overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population- Review of the performance of the leading drugs in...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs Scope Overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population Review of the performance of the leading drugs in the market, Pfizer’s Detrol (tolterodine) and ALZA’s Ditropan XL (oxybutynin chloride) Analysis of the potential of Yamanouchi’s Vesicare (solifenacin succinate),...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
PDF cover 0515.qxd This weeks UK PDJ reports the expiry of the SPC awarded to Prodes SA for aceclofenac on 18th March, 2005.darifenacin hydrobromide.Enablex, darifenacin was approved for the treatment of overactive bladder (OAB) by the FDA in December 2004...
author: MSparrowhawk
PDF cover 0515.qxd page 1
author: MSparrowhawk
Gazette Weekly Highlights News - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - - Current Patents Gazette - Weekly Highlights News The gazette weekly highlights focuses on patent-related issues making the headlines, on noteworthy new applications, and on litigation and legislation affecting the industry.
http://www.novartis.com/downloads_new/investors/Q205_press_release_final.pdf Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA (1) Pro forma basis: This report reflects the adoption of new IFRS accounting standards that became effective on January 1, 2005, and other presentational changes.
duplicates:http://www.novartis.com/downloads_new/investors/Q205_press_release_final.pdf
http://www.novartis.com/downloads_new/investors/Q205_press_release_final.pdf page 9
duplicates:http://www.novartis.com/downloads_new/investors/Q205_press_release_final.pdf
Urinary Incontinence: Growing market offers commercial opportunity - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
http://www.novartis.com/downloads_new/investors/full_year_2004_results_release.pdf Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA All product names appearing in italics are trademarks of Novartis Group Companies Unless otherwise stated, growth rates are in USD and comments refer to full- year 2004 figures 1/ 25 Investor Relations Release Novartis delivers record results with...
duplicates:http://www.novartis.com/downloads_new/investors/full_year_2004_results_release.pdf
http://www.novartis.com/downloads_new/investors/full_year_2004_results_release.pdf page 17
duplicates:http://www.novartis.com/downloads_new/investors/full_year_2004_results_release.pdf
Novartis Press Kit English page 16
author: guestnc1
duplicates:http://www.novartis.com/downloads/press_kit.pdf
Database D D - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
Database E E - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
http://www.novartis.com/downloads_new/about/NOVARTIS_480.pdf 10 Novartis Group Therapeutic area Project/ compound Generic name Indication Cardiovascular Diovan valsartan Congestive heart failure and metabolism Diovan VALIANT valsartan Post- myocardial infarction Lotrel 10TH 40, 5TH 40 benazepril, amlodipine Hypertension Diovan VALUE valsartan High risk hypertension Navigator* valsartan, nateglinide Progression to type- II diabetes Sandostatin...
http://www.novartis.com/downloads_new/about/NOVARTIS_480.pdf page 1
duplicates:http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
e_UG_s01_s44 Contents Facts & Figures 2003/ 2004 Caring and Curing Contents Overview 01 Who We Are 02 Operations: sales, income and activities 04 Financial and Share Information Businesses 10 Pharmaceuticals 12 Development Pipeline 15 Corporate Research 16 Consumer Health 18 Sandoz 19 OTC 20 Animal Health 21 Medical Nutrition 22 Infant & Baby 23 CIBA Vision Corporate Functions 24 Management 25...
author: mac_36
duplicates:http://www.novartis.com/downloads_new/news/Novartis%20FactsFigures%202003_2004%20E.pdf
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf Novartis Group 1 Overview 2 Financial Highlights 3 News in 2003 Letter from Daniel Vasella 5 The New Number Five in Pharmaceuticals Division and Business Units 9 Pharmaceuticals Giving Thalassemia Patients a Choice Discovering Pharmaceuticals Reliably and Predictably The Long Road to Blood- Pressure Control Treating Breast Cancer Will Never Be the Same Epilepsy Putting Children First...
duplicates:http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf page 106
duplicates:http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf 1 Attractive Projects in Important Public Health Issues Jean- Jacques Garaud Head of Clinical Research & Development, Novartis Pharma AG 2 R& D Day_ 2003- 11- 19_ Jean Garaud ue ue ue ue ue ue Gold standard potential ue II QAB149 (asthma, COPD 2 ) ue ue II TCH346 (neurodegeneration) ue ue II SPP100 (hypertension) ue ue II LAF237 (type 2 diabetes) III LDT600 (hepatitis B) ue ue III...
duplicates:http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf
http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf page 20
duplicates:http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf http://www.novartis.com/downloads_new/investors/j_g_rnd_day_2003.pdf
http://www.phrma.org/newmedicines/resources/2003-09-02.117.pdf 3 M E D I C I N E S I N D E V E L O P M E N T F O R Older American 2003 A L Z H E I M E R' S D I S E A S E/ DE M E N T I A S Product Name Spon or Indication Development Statu Reminyl ® Johnson & Johnson Alzheimer's dementia application submitted galantamine Pharmaceutical (extended- release formulation) (800) 817- 5286 Research & Development Raritan, NJ mixed and vascular...
http://www.phrma.org/newmedicines/resources/2003-09-02.117.pdf page 3
Res&Buyside 8"x10.75_4 pager Think what's possible
author: Dean Pillion
duplicates:http://www.novartis.com/downloads/fact_sheet_Sep_2003.pdf http://www.novartis.com/downloads/fact_sheet_Sep_2003.pdf
Res&Buyside 8"x10.75_4 pager page 1
author: Dean Pillion
duplicates:http://www.novartis.com/downloads/fact_sheet_Sep_2003.pdf http://www.novartis.com/downloads/fact_sheet_Sep_2003.pdf
